Price to Sales (P/S)
since 2005
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Long-term (Investment) Activity Ratios
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Eli Lilly & Co., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenue1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Eli Lilly & Co. Annual Report.
The analysis of the financial data over the annual periods reveals several key trends in share price, sales per share, and price-to-sales (P/S) ratio.
- Share Price
- The share price exhibited an initial decline from US$55.89 in 2006 to a low of US$29.38 in 2009. Subsequently, there was a steady upward trend, with the share price increasing substantially to US$867.05 by 2025. Notably, the pace of growth accelerated after 2013, with particularly sharp increases observed from 2018 onward.
- Sales per Share
- Sales per share showed a generally consistent upward trajectory throughout the period. Beginning at US$12.96 in 2006, sales per share reached US$47.50 by 2025. While growth was relatively moderate in the early years and exhibited some fluctuations around 2013 to 2015, the trend from 2015 onwards points to a solid increase in sales per share, suggesting improved operational performance or increased revenue generation per share over time.
- Price-to-Sales (P/S) Ratio
- The P/S ratio experienced significant fluctuations throughout the observed years. Initially, the ratio declined sharply from 4.31 in 2006 to 1.66 in 2009, reflecting the drop in share price relative to sales per share. After 2009, the ratio increased consistently, reaching a peak value of 20.77 in 2024 before slightly declining to 18.25 in 2025. This rising trend in the P/S ratio indicates growing investor confidence and valuation multiples, with the market placing increasingly higher value on each unit of sales.
- Overall Insights
- There is a clear pattern of recovery and substantial growth in market valuation after a period of decline during 2006-2009. Sales per share growth has been steady, supporting a healthy revenue generation trend. The rapidly increasing share price and P/S ratio, particularly in recent years, suggest strong market optimism or expectations for future profitability. The divergence between share price growth and more moderate sales per share growth indicates that factors beyond current sales, such as anticipated growth, innovation, or market positioning, may be influencing investor valuation.
Comparison to Competitors
Eli Lilly & Co., P/S, long-term trends, comparison to competitors
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | ||||||||||||
| Feb 21, 2024 | ||||||||||||
| Feb 22, 2023 | ||||||||||||
| Feb 23, 2022 | ||||||||||||
| Feb 17, 2021 | ||||||||||||
| Feb 19, 2020 | ||||||||||||
| Feb 19, 2019 | ||||||||||||
| Feb 20, 2018 | ||||||||||||
| Feb 21, 2017 | ||||||||||||
| Feb 19, 2016 | ||||||||||||
| Feb 19, 2015 | ||||||||||||
| Feb 19, 2014 | ||||||||||||
| Feb 21, 2013 | ||||||||||||
| Feb 24, 2012 | ||||||||||||
| Feb 22, 2011 | ||||||||||||
| Feb 22, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 29, 2008 | ||||||||||||
| Feb 28, 2007 | ||||||||||||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Eli Lilly & Co., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Eli Lilly & Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 19, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 17, 2021 | ||
| Feb 19, 2020 | ||
| Feb 19, 2019 | ||
| Feb 20, 2018 | ||
| Feb 21, 2017 | ||
| Feb 19, 2016 | ||
| Feb 19, 2015 | ||
| Feb 19, 2014 | ||
| Feb 21, 2013 | ||
| Feb 24, 2012 | ||
| Feb 22, 2011 | ||
| Feb 22, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Feb 28, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Eli Lilly & Co., P/S, long-term trends, comparison to industry (health care)
| Eli Lilly & Co. | Health Care | |
|---|---|---|
| Feb 19, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 17, 2021 | ||
| Feb 19, 2020 | ||
| Feb 19, 2019 | ||
| Feb 20, 2018 | ||
| Feb 21, 2017 | ||
| Feb 19, 2016 | ||
| Feb 19, 2015 | ||
| Feb 19, 2014 | ||
| Feb 21, 2013 | ||
| Feb 24, 2012 | ||
| Feb 22, 2011 | ||
| Feb 22, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Feb 28, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).